Search for: "Rachel Sachs" Results 81 - 100 of 106
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
How is the NIH seeking to encourage investment in diagnostic testing for COVID-19?
13 Aug 2020, 8:09 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Are COVID-19 vaccine advance purchases a form of vaccine nationalism, an effective spur to innovation, or something in between?
5 Aug 2020, 11:43 am by Lisa Larrimore Ouellette
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Structural Racism and COVID-19
11 Jun 2020, 2:30 pm by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
SEC Unveils Controversial ESG Disclosure Rule Proposal
12 Mar 2023, 2:05 pm by Race to the Bottom
The proposal has supporters in the private industry, as well; Rachel Glaser, CFO at Etsy, sees the rule [read post]
The Race to the Bottom - https://www.theracetothebottom.org/rttb
What are the challenges in developing information around mixing-and-matching COVID-19 vaccines and therapies?
21 Jan 2022, 8:35 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How can health regulators maintain public trust when facing scientific uncertainty?
24 Jun 2020, 5:36 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Regulatory Responses to N95 Respirator Shortages
21 Apr 2020, 2:09 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOur recent posts have highlighted [read post]
Written Description - http://writtendescription.blogspot.com/
How can innovation and regulatory policy accomplish robust COVID-19 testing?
15 Apr 2020, 8:14 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowIt’s now clear that [read post]
Written Description - http://writtendescription.blogspot.com/
Why do differences in clinical trial design make it hard to compare COVID-19 vaccines?
30 Jun 2021, 10:31 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How are COVID-19 vaccine developers and regulators responding to variants?
25 Mar 2021, 1:24 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What can policymakers learn from the disastrously slow COVID-19 vaccine rollout?
12 Jan 2021, 9:04 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How will the FDA’s new COVID-19 vaccine guidance affect development efforts?
10 Jul 2020, 8:59 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Molnupiravir may become the first COVID-19 pill. What took so long?
5 Nov 2021, 8:20 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing?
25 Aug 2020, 4:50 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Remdesivir Part I: Incentivizing Antiviral Innovation
12 May 2020, 7:49 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What does it mean that Oracle is partnering with the Trump administration to study unproven COVID-19 drugs?
30 Mar 2020, 8:40 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOne of the dizzying stream [read post]
Written Description - http://writtendescription.blogspot.com/
Posthumous Justice for Lawyers
9 May 2014, 2:14 pm
Chang’s descendants remain in the San Francisco Bay Area, including grandniece Rachelle Chong [read post]
Ratio Juris - http://ratiojuris.blogspot.com/
What does ending the COVID-19 pandemic mean from a legal perspective?
8 Jun 2022, 5:23 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
#IPSC18 Preview: Patents & Innovation
30 Jul 2018, 10:44 am by Lisa Ouellette
Stefania Fusco et al. and me & Andrew Tutt in Breakout 6 – IP and Academic Institutions, and Rachel [read post]
Written Description - http://writtendescription.blogspot.com/
Guest Post: Spurring and Clearing the Path for Open COVID Innovation Through Contextual Patent Disclosure
20 May 2020, 1:58 pm by Jason Rantanen
related to COVID by a team of Professors including, in addition to Professor Ouellette, Jake Sherkow, Rachel [read post]
Patently-O - https://patentlyo.com